Therefore, our primary innovation lies in the novel insight that targeting METTL3 in T cells, rather than tumour cells, is essential for maintaining T‐cell persistence and, therefore, potentiates the efficacy of anti‐PD‐1 therapy. Here, METTL3 is linked to neoplasm.